Skip to main content

Research Repository

Advanced Search

All Outputs (42)

Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study (2009)
Journal Article
Dueland, S., Aamdal, S., Lind, M. J., Thomas, H., Sandvold, M. L., Gaullier, J., & Rasch, W. (2009). Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study. Acta Oncologica, 48(1), 137-145. https://doi.org/10.1080/02841860802183620

Purpose. Cytarabine (ara-C) has limited activity in solid tumours. CP-4055 (ELACYTT) is a novel ara-C-5'-elaidic acid ester that may circumvent this limitation. CP-4055 maximum tolerated dose (MTD), pharmacokinetics and antitumor activity have been i... Read More about Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study.

The proteomic analysis of resistance to anticancer therapy in human breast cancer (2006)
Thesis
Smith, L. (2006). The proteomic analysis of resistance to anticancer therapy in human breast cancer. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4212607

Resistance to anticancer therapy represents a major barrier in the successful management of human breast cancer. The identification of novel biomarkers that correlate with treatment response would increase our understanding of the resistance mechanis... Read More about The proteomic analysis of resistance to anticancer therapy in human breast cancer.